Patents Represented by Attorney Lucy J. Incyte Pharmaceuticals, Inc. Billings
-
Patent number: 5833981Abstract: The present invention provides a novel human phosphorylase kinase gamma subunit (HPHKG) and the polynucleotide which identifies and encodes HPHKG. The invention provides for expression vectors and host cells comprising the nucleic acid sequence encoding HPHKG. The invention also provides pharmaceutical compositions containing purified HPHKG or antisense molecules to HPHKG for the treatment of diseases associated with expression of HPHKG. The invention also includes diagnostic compositions containing the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding HPHKG or anti-HPHKG antibodies which specifically bind to HPHKG, and the use of such compositions for diagnosis of disease.Type: GrantFiled: August 28, 1997Date of Patent: November 10, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli
-
Patent number: 5834241Abstract: The present invention provides a human vesicle trafficking protein (HVTP) and polynucleotides which identify and encode HVTP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing HVTP and for treating or preventing disorders associated with expression of HVTP.Type: GrantFiled: May 6, 1997Date of Patent: November 10, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Preeti Lal, Neil C. Corley
-
Patent number: 5834192Abstract: The present invention provides a polynucleotide (hcap) isolated from a breast tumor library which identifies and encodes a human cachexia-associated protein (HCAP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HCAP. The invention also provides for the therapeutic use of purified HCAP in the treatment of severe or moderate obesity, and for the therapeutic use of antisense molecules, antibodies, antagonists or inhibitors in the treatment of tumor-induced cachexia. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, or fragments thereof, or antibodies which specifically bind to the polypeptide.Type: GrantFiled: April 5, 1996Date of Patent: November 10, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Ingrid Erika Akerblom, Lynn E. Murry
-
Patent number: 5834242Abstract: The present invention provides a new human clathrin-associated protein (CLAPH) and polynucleotides which identify and encode CLAPH. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of CLAPH, as well as diagnostic assays.Type: GrantFiled: May 1, 1997Date of Patent: November 10, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Neil C. Corley, Purvi Shah
-
Patent number: 5834240Abstract: The present invention provides a transforming growth factor-.beta. receptor associated protein (TGFAS) and polynucleotides which identify and encode TGFAS. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of TGFAS.Type: GrantFiled: March 28, 1997Date of Patent: November 10, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Preeti Lal
-
Patent number: 5830660Abstract: The present invention provides a human tumorigenesis protein (HTAP) and polynucleotides which identify and encode HTAP. In addition, the invention provides expression vectors and host cells, agonists, antibodies, and antagonists. The invention also provides methods for producing HTAP and for treating or preventing disorders associated with the expression of HTAP.Type: GrantFiled: March 20, 1997Date of Patent: November 3, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5831049Abstract: The present invention provides a human thioredoxin (TRDX) and polynucleotides which identify and encode TRDX. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding TRDX and a method for producing TRDX. The invention also provides for agonists, antibodies, or antagonists specifically binding TRDX, and their use, in the prevention and treatment of diseases associated with expression of TRDX. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding TRDX for the treatment of diseases associated with the expression of TRDX. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding TRDX in the production of recombinant proteins. The invention also provides for the use of purified TRDX in the production of recombinant proteins.Type: GrantFiled: January 3, 1997Date of Patent: November 3, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5824500Abstract: The present invention provides a novel human KDEL receptor (NHKR) and polynucleotides which identify and encode NHKR. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NHKR and a method for producing NHKR. The invention also provides for agonists, antibodies, or antagonists specifically binding NHKR, and their use, in the prevention and treatment of diseases associated with expression of NHKR. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NHKR for the treatment of diseases associated with the expression of NHKR. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NHKR.Type: GrantFiled: November 21, 1996Date of Patent: October 20, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5817482Abstract: The invention provides human nucleotide kinases and polynucleotides which identify and encode DRNK. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of DRNK.Type: GrantFiled: June 20, 1997Date of Patent: October 6, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Jennifer L. Hillman, Phillip R. Hawkins, Karl J. Guegler, Neil C. Corley
-
Patent number: 5817494Abstract: The present invention provides a human ubiquitin conjugation system protein (UCSP) and polynucleotides which encode UCSP. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of UCSP.Type: GrantFiled: May 21, 1997Date of Patent: October 6, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Neil C. Corley, Preeti Lal, Purvi Shah
-
Patent number: 5811520Abstract: The present invention provides a polynucleotide (gipl) the partial sequence for which was initially isolated from a THP-1 cDNA library and which identifies and encodes a novel human phospholipase inhibitor (GIPL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding GIPL. The invention also provides for the use of purified GIPL and its agonists in pharmaceutical compositions for the treatment of diseases associated with the abnormal or excess phospholipase activity. Additionally, the invention provides for the use of antisense molecules to gipl or inhibitors of GIPL in pharmaceutical compositions for the prevention of pregnancy or treatment of Alzheimer's disease.Type: GrantFiled: August 29, 1997Date of Patent: September 22, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Phillip R. Hawkins, Lynn E. Murry
-
Patent number: 5804419Abstract: The invention provides a human calcium-binding phosphoprotein (CBPP-1) and polynucleotides which identify and encode CBPP-1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of CBPP-1.Type: GrantFiled: June 27, 1997Date of Patent: September 8, 1998Assignee: Incyte Pharmaceuticles, Inc.Inventors: Olga Bandman, Neil C. Corley, Purvi Shah
-
Patent number: 5783669Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode the hyaluronan receptor (hr) from human umbilical vein endothelial cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode hr, expression vectors for the production of purified HR, antibodies capable of binding specifically to HR, hybridization probes or oligonucleotides for detecting the upregulation of HR encoding nucleotide sequences, genetically engineered host cells for the expression of HR, diagnostic tests for activated, angiogenic, inflamed or metastatic cells and/or tissues based on HR-encoding nucleic acid molecules and antibodies capable of binding specifically to the receptor.Type: GrantFiled: August 20, 1996Date of Patent: July 21, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Phillip R. Hawkins, Craig G. Wilde, Jeffrey J. Seilhamer
-
Patent number: 5683910Abstract: The present invention provides a novel human phosphorylase kinase gamma subunit (HPHKG) and the polynucleotide which identifies and encodes HPHKG. The invention provides for expression vectors and host cells comprising the nucleic acid sequence encoding HPHKG. The invention also provides pharmaceutical compositions containing purified HPHKG or antisense molecules to HPHKG for the treatment of diseases associated with expression of HPHKG. The invention also includes diagnostic compositions containing the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding HPHKG or anti-HPHKG antibodies which specifically bind to HPHKG, and the use of such compositions for diagnosis of disease.Type: GrantFiled: September 13, 1996Date of Patent: November 4, 1997Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli
-
Patent number: 5663059Abstract: The present invention provides a polynucleotide (gipl) the partial sequence for which was initially isolated from a THP-1 cDNA library and which identifies and encodes a novel human phospholipase inhibitor (GIPL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding GIPL.Type: GrantFiled: May 23, 1996Date of Patent: September 2, 1997Assignee: Incyte Pharmaceuticals, Inc.Inventors: Phillip R. Hawkins, Lynn E. Murry
-
Patent number: 5654146Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new human interleukin-1 converting enzyme homolog (ICEY). The present invention also provides for expression vectors for the production of purified ICEY, hybridization probes for the detection of ICEY-encoding nucleotide sequences, genetically engineered host cells for the expression of ICEY, diagnostic tests for ICEY or for polynucleotides encoding ICEY, and use of the protein to produce antibodies capable of binding specifically to the protein and use of the protein to screen for inhibitors.Type: GrantFiled: May 31, 1995Date of Patent: August 5, 1997Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott Michael Braxton, Angelo M. Delegeane, Dinh Diep
-
Patent number: 5648238Abstract: The present invention provides a polynucleotide (ipkc) which identifies and encodes a novel human protein kinase C inhibitor homolog (IPKC). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding IPKC.Type: GrantFiled: June 18, 1996Date of Patent: July 15, 1997Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman
-
Patent number: 5648239Abstract: The present invention provides a polynucleotide (ipka) which identifies and encodes a novel human cAMP-dependent protein kinase A inhibitor homolog (IPKA). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding IPKA.Type: GrantFiled: June 21, 1996Date of Patent: July 15, 1997Assignee: Incyte Pharmaceuticals, Inc.Inventors: Phillip R. Hawkins, Jennifer L. Hillman, Janice Au-Young